GoodRx (NASDAQ:GDRX) Price Target Increased to $8.00 by Analysts at Deutsche Bank Aktiengesellschaft

GoodRx (NASDAQ:GDRX – Get Rating) had its price target hoisted by Deutsche Bank Aktiengesellschaft from $7.00 to $8.00 in a report released on Tuesday, The Fly reports.

Several other research analysts have also commented on the company. Wells Fargo & Company lifted their price target on GoodRx from $5.50 to $6.00 and gave the stock an equal weight rating in a report on Wednesday, March 1st. The Goldman Sachs Group reduced their price target on shares of GoodRx from $8.00 to $7.00 and set a neutral rating on the stock in a research report on Wednesday, March 1st. DA Davidson lowered their price objective on GoodRx to $5.00 in a research report on Tuesday, November 15th. Truist Financial decreased their price target on GoodRx to $6.00 in a research note on Wednesday, November 16th. Finally, Barclays cut their price objective on GoodRx from $9.00 to $8.00 and set an overweight rating for the company in a research report on Wednesday, January 18th. Thirteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Hold and a consensus price target of $7.97.

GoodRx Price Performance

NASDAQ:GDRX opened at $5.50 on Tuesday. GoodRx has a one year low of $3.82 and a one year high of $20.59. The stock has a market cap of $2.18 billion, a PE ratio of -78.56, a P/E/G ratio of 12.41 and a beta of 0.84. The company has a debt-to-equity ratio of 0.80, a quick ratio of 12.05 and a current ratio of 12.05. The stock has a 50 day moving average price of $5.26 and a 200 day moving average price of $5.24.

Hedge Funds Weigh In On GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC lifted its stake in GoodRx by 112,694.0% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company’s stock worth $79,910,000 after acquiring an additional 17,132,866 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of GoodRx by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 7,830,341 shares of the company’s stock worth $36,568,000 after purchasing an additional 739,017 shares during the last quarter. Millennium Management LLC grew its stake in shares of GoodRx by 151.3% during the fourth quarter. Millennium Management LLC now owns 5,318,603 shares of the company’s stock worth $24,785,000 after purchasing an additional 3,202,061 shares in the last quarter. Light Street Capital Management LLC increased its holdings in GoodRx by 10.0% in the second quarter. Light Street Capital Management LLC now owns 4,629,276 shares of the company’s stock valued at $27,405,000 after buying an additional 420,123 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in GoodRx by 1.5% in the third quarter. Marshall Wace LLP now owns 3,622,709 shares of the company’s stock valued at $16,916,000 after buying an additional 55,218 shares in the last quarter. 35.22% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.